Meet our new CFO!
PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.
Alexander assumed the role of CFO in August and will leverage his extensive cross-industry experience to lead the company's financial functions. With a comprehensive background as a CFO, including his previous role at Coegin Pharma, and recent consultancy for small to medium-sized businesses, his insights will be integral in supporting our mission to develop safe and effective treatments for neuropathic pain. Alexander Dahlquist will play a significant role in supporting the company's journey ahead.
Meet our new CFO!
PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.
Alexander assumed the role of CFO in August and will leverage his extensive cross-industry experience to lead the company's financial functions. With a comprehensive background as a CFO, including his previous role at Coegin Pharma, and recent consultancy for small to medium-sized businesses, his insights will be integral in supporting our mission to develop safe and effective treatments for neuropathic pain. Alexander Dahlquist will play a significant role in supporting the company's journey ahead.
Latest news
View all
Phase I study completed for PN6047
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read more
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more